17 January 2018 - - Aliso Viejo, California-based clinical genetic diagnostics specialist Ambry Genetics Corp. has appointed Linh H. Le as chief operating officer, the company said.
Linh's primary role will be to develop a scalable operational strategy as Ambry expands its reach globally, following a successful acquisition by Konica Minolta.
Konica Minolta closed its acquisition of Ambry in late October, with a mission to combine the companies' technologies into a global solution for precision medicine. Le will contribute heavily towards ensuring Ambry's operations are well-prepared to achieve that goal.
Linh brings more than 25 years of work experience, stemming from several industry sectors including medical devices, biopharmaceutical, entertainment and management advisory services.
He spent the last 14 years in the healthcare industry overseeing financial operations at Medtronic's diabetes intensive insulin business unit.
Prior to that, Linh held leadership roles at the Walt Disney Company, PricewaterhouseCoopers, Twentieth Century Fox, and KPMG.
Ambry Genetics provides clinical genetic diagnostics and software solutions. The company has established a reputation for sharing data while safeguarding patient privacy, unparalleled service, and responsibly applying new technologies to the clinical molecular diagnostics market.